Coherus and Daiichi Sankyo terminate Enbrel biosimilar project

|About: Coherus BioSciences (CHRS)|By:, SA News Editor

In an 8-K filed today, Coherus Biosciences (NASDAQ:CHRS) reports that it and Daiichi Sankyo (OTCPK:DSKYF) inked a letter of agreement on August 9 terminating their January 23, 2012 agreement related to the development of CHS-0214, a biosimilar to Amgen's Enbrel (etanercept), in Japan. The company says it will not incur any early termination penalties resulting from the action.

Subscribe for full text news in your inbox